Arcus Biosciences Return on Investment 2017-2022 | RCUS

Current and historical return on investment (ROI) values for Arcus Biosciences (RCUS) over the last 10 years.
Arcus Biosciences ROI - Return on Investment Historical Data
Date TTM Net Income LT Investments & Debt Return on Investment
2022-03-31 $0.06B inf%
2021-12-31 $0.05B inf%
2021-09-30 $-0.28B inf%
2021-06-30 $-0.20B inf%
2021-03-31 $-0.17B inf%
2020-12-31 $-0.12B inf%
2020-09-30 $-0.09B inf%
2020-06-30 $-0.11B inf%
2020-03-31 $-0.10B inf%
2019-12-31 $-0.09B inf%
2019-09-30 $-0.08B inf%
2019-06-30 $-0.07B inf%
2019-03-31 $-0.06B inf%
2018-12-31 $-0.05B inf%
2018-09-30 $-0.05B inf%
2018-06-30 $-0.07B inf%
2018-03-31 $-0.06B inf%
2017-12-31 $-0.05B inf%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.901B $0.383B
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00